Advances and Challenges in RAS-Directed Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (10 August 2024) | Viewed by 224
Special Issue Editors
Interests: RAS signaling; cancer therapy; structural biology; molecular simulation
Special Issues, Collections and Topics in MDPI journals
2. Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China
Interests: ultrasound imaging; thyroid ablation; artificial intelligence; molecular imaging; tumor development
Special Issue Information
Dear Colleagues,
Oncogenic RAS mutations, such as G12C, G12D, G13D, and Q61H, are some of the most frequently mutated genes causing cancer. Multiple strategies have been developed to directly target the aberrant activation of RAS signaling to treat cancer, including prenylation inhibitors, PDEδ inhibitors, and SHP2 inhibitors, but none have advanced to use in the clinic. Recently approved KRAS G12C inhibitors justified KRAS as a target and, significantly, demonstrated that specific RAS mutant can be selectively targeted. However, KRAS G12C is the only RAS mutant that has been successfully targeted so far in human cancer patients, which limits its application for targeting other oncogenic RAS mutant-driven cancers.
Recently, new approaches have inspired optimism regarding targeting certain KRAS mutations, including G12D, G13D, and Q61H, based on epidemiological data suggesting that cancers harboring different RAS mutants exhibit distinct clinical behaviors. These differences suggest that unique functional classes of oncogenic RAS alleles will be differentially regulated and will have distinct vulnerabilities in cancer therapy. This concept may also apply to equivalent mutations in HRAS and NRAS.
This Special Issue will cover subjects related to recent progress in RAS-directed therapeutic approaches in cancer therapy and the underlying mechanisms for acquired drug resistance. The hope is that it will increase our understanding of the clinical efficacy and challenges of RAS targeting therapy in different cancers.
Dr. Zhiwei Zhou
Dr. Xi Wei
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RAS
- RAS targeting therapy
- drug resistance
- structural basis
- cancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
